Carcinoid Syndrome News and Research

RSS
Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Pancreas releases new NANETS guidelines on rare group of cancers

Pancreas releases new NANETS guidelines on rare group of cancers

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon acquires equity shares of Symphony Icon Holdings

Lexicon acquires equity shares of Symphony Icon Holdings

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals first-quarter revenues down 61%

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Indevus Pharmaceuticals enters merger agreement with Endo Pharmaceuticals

Indevus Pharmaceuticals enters merger agreement with Endo Pharmaceuticals